Incyte's Q2 2026 results mark a strategic inflection, with revenue surging 37.7% year-over-year to $1.7B and operating margin expanding to 41.7%, signaling successful diversification beyond Jakafi. The fortress balance sheet, featuring $4.0B cash and near-zero...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue accelerated 37.7% YoY to $1.7B in Q2 2026, with gross margin holding at 93.7% and operating margin surging to 41.7%, demonstrating strong operating leverage.
Incyte reported positive topline Phase 3 frontMIND results for tafasitamab (Monjuvi/Minjuvi) and lenalidomide combination, improving progression-free survival in high-risk diffuse large B-cell lymphoma.
Incyte's Q4 and full-year 2025 results showed revenue growth to US$1.51 billion and US$5.14 billion, respectively, with higher net income and earnings per share.
A bull case scenario suggests Opzelura adoption could accelerate dramatically, pushing annual revenue growth toward 10-12%.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 28, 2026 | $3.09+43.7% vs $2.15 | $1.7B+11.3% vs $1.5B |
Q2 2026 Apr 28, 2026 | $1.81+35.1% vs $1.34 | $1.3B+4.7% vs $1.2B |
Q1 2026 Feb 10, 2026 | $1.80-5.3% vs $1.90 | $1.5B+11.2% vs $1.4B |
Q4 2025 Oct 28, 2025 | $2.26+36.1% vs $1.66 | $1.4B+0.9% vs $1.4B |
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio.
The First Trust Large Cap Growth AlphaDEX ETF (FTC) was launched on 05/08/2007, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Growth category of the market.
Incyte (NASDAQ: INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company's pipeline has changed substantially over the past year, citing proof-of-concept data for its CALR antibody 989 in myelofibrosis and
/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte
Benchmark INCY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Incyte Corporation (INCY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $126.93 | $25.73B | 19.80 | 21.22% | 25.03% | 29.87% | — | |
| $43.29 | $7.26B | 30.27 | -5.25% | 3.96% | 3.72% | — | |
| $240.57 | $15.11B | -41.19 | 4.88% | 20.45% | 21.37% | — | |
| $58.15 | $14.62B | 20.92 | 6.98% | 35.33% | 42.49% | — | |
| $115.13 | $13.66B | 44.97 | 37.55% | 24.86% | 180.63% | — | |
| $45.75 | $7.6B | -19.22 | 33.87% | -64.64% | -110.84% | — |
Incyte Corporation (INCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Incyte Corporation (INCY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 28, 2026·SEC
Jul 6, 2026·SEC
Jun 22, 2026·SEC
Get notified when INCY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Incyte Corporation (INCY) stock FAQ — growth, dividends, profitability & financials explained
Incyte Corporation (INCY) reported $5.82B in revenue for fiscal year 2025. This represents a 13789% increase from $41.9M in 1996.
Incyte Corporation (INCY) grew revenue by 21.2% over the past year. This is strong growth.
Yes, Incyte Corporation (INCY) is profitable, generating $1.61B in net income for fiscal year 2025 (25.0% net margin).
Incyte Corporation (INCY) has a return on equity (ROE) of 29.9%. This is excellent, indicating efficient use of shareholder capital.
Incyte Corporation (INCY) generated $1.92B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
